A novel macrolide, solithromycin suppresses mucin overexpression induced by Pseudomonas aeruginosa LPS in airway epithelial cells. Issue 9 (September 2020)

• Record Type: Journal Article
• Authors: Kawamoto, Yasuhide; Morinaga, Yoshitomo; Kaku, Norihito; Uno, Naoki; Kosai, Kosuke; Sakamoto, Kei; Hasegawa, Hiroo; Yanagihara, Katunori
• Is Part Of: Journal of infection and chemotherapy. Volume 26:Issue 9(2020:Sep.)
• Page Start: 1008
• Page End: 1010
• Publication Date: 2020-09
• Subjects: MUC5AC -- Immunomodulatory effect -- Azithromycin; Chemotherapy -- Periodicals; Infection -- Periodicals; Communicable diseases -- Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1016/j.jiac.2020.06.014
• Languages: English
• ISSNs: 1341-321X

Abstract

Abstract: Some macrolides such as 14- and 15-membered macrolides have immunomodulatory effects such as suppression of mucin overproduction. Because a novel macrolide, solithromycin, was developed, we examined whether it suppresses the overexpression of mucin in vitro. A human airway epithelial cell line NCI–H292 was stimulated by Pseudomonas aeruginosa lipopolysaccharides to induce the overproduction of a major mucin, MUC5AC. Treatment with 10 μg/mL of solithromycin significantly inhibited LPS-induced MUC5AC in both mRNA and protein levels as well as a 15-membered macrolide, azithromycin. These findings support that solithromycin has a potential immunomodulatory effect.